

Haematologica
HAEMATOL/2015/124347
Version 3

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial

Disclosures: The GMMG MM5 Trial (EudraCT no. 2010-019173-16) is supported by grants from Janssen-Cilag, Celgene, Chugai and The Binding Site. Disclosures (in alphabetical order): Dr. Bertsch reports grants and other contributions from Janssen-Cilag as well as grants and other contributions from Celgene and grants from Chugai during the conduct of the study. Dr. Blau has nothing to disclose. Dr. Dürig reports Honoraria and Consultancy fees provided by Janssen Cilag, and Honoraria from Celgene. Dr. Gerecke has nothing to disclose. Dr. Goldschmidt reports grants, personal fees and other from Janssen, grants, personal fees and other from Celgene, grants, personal fees and other from Novartis, grants and personal fees from Chugai, personal fees and other from Onyx, personal fees and other from Millennium, grants and other from BMS outside the submitted work. Dr. Hänel has nothing to disclose. Dr. Hielscher has nothing to disclose. Dr. Hillengass reports other contributions from Celgene and from Janssen as well as from Medtronic outside the submitted work. Dr. Hose reports grants from Sanofi-Aventis, grants from EngMab AG, personal fees from Celgene, outside the submitted work.; .Dr. Jauch has nothing to disclose. Dr. Kunz has nothing to disclose. Dr. Lindemann has nothing to disclose. Dr. Mai reports other contributions from Janssen-Cilag, Onyx, Celgene and from Mundipharma during the conduct of the study. Dr. Merz reports other contributions from Janssen, and Celgene during the conduct of the study. Dr. Munder reports personal fees from Bristol-Myers Squibb outside the submitted work. Dr. Raab has nothing to disclose. Dr. Salwender reports personal fees from Celgene, from Janssen Cilag and Binding site outside the submitted work. Dr. Scheid reports honoraria from Janssen, Celgene and Novartis outside the submitted work. Dr. Schmidt-Wolf reports personal fees from Janssen Cilag and Novartis during the conduct of the study. Dr. Schurich has nothing to disclose. Dr. Seckinger has nothing to disclose. Dr. Weisel reports personal fees and non-financial support from Celgene and grants, personal fees and non-financial support from Janssen during the conduct of the study as well as personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Celgene, personal fees from Noxxon, personal fees and non-financial support from BMS, personal fees and non-financial support from Onyx, personal fees and non-financial support from AMGEN outside the submitted work. Dr. Zeis has nothing to disclose.

Contributions: HG is the principal investigator of the study UB and HG wrote the study protocol MM, EKM, UB, CK, TH and HG analyzed and interpreted the data MM and HG wrote the manuscript CK and TH performed statistical analysis UB and BS are responsible for data acquisition and monitoring MM, HS, MH, EKM, UB, IWB, CS, DH, JH, MSR, MM, IGHSW, CG, HWL, MZ, KW and JD contributed with the inclusion of patients DH, AS and AJ performed plasma cell sorting and FISH analysis